Search

Displaying results 9531 - 9540 of 10000 in total
  1. Drug

    OTL-203

    go.drugbank.com/drugs/DB18643
    Investigational

    OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.

    Synonyms: Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene
  2. Drug

    Dichlorophen

    go.drugbank.com/drugs/DB11396
    InvestigationalVet approved

    Dichlorophen is an antimicrobial agent shown to exert activity against cestodes, protozoa, fungi, and bacteria.

  3. Drug

    Vafidemstat

    go.drugbank.com/drugs/DB16446
    Investigational

    Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease).

  4. Drug

    INKP-102

    go.drugbank.com/drugs/DB05326
    Experimental

    INKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.

  5. Drug

    STI-1499

    go.drugbank.com/drugs/DB16487
    Investigational

    STI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.

  6. Drug

    MK-4541

    go.drugbank.com/drugs/DB17016
    Experimental

    MK-4541 is a 4-azasteroid and a selective androgen receptor modulator (SARM). MK-4541 acts as a dual selective SARM and is both a potent androgen receptor antagonist and a 5α-reductase inhibitor.

  7. Drug

    Tulisokibart

    go.drugbank.com/drugs/DB18719
    Investigational

    PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15.

  8. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  9. Drug

    PR-104

    go.drugbank.com/drugs/DB05968
    Investigational

  10. Drug

    RDP58

    go.drugbank.com/drugs/DB06566
    Experimental

    of inflammatory cytokines. … RDP58 (NH2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression